GLP1R and type 2 diabetes mellitus: Results from a large US administrative claims database revealed that, compared with the use of a DPP-4i, OW GLP-1 RA use among people with T2D and established ASCVD is associated with 26% lower ischemic stroke risk and 22% lower MI risk, along with significant reductions in ASCVD-related hospitalizations and outpatient visits; all-cause hospitalizations, ER visits, and outpatient visits; and ASCVD-related and all-cause hospitalization costs and total medical costs.